CAPhO 2024 Sandoz On-Demand Symposium: Breaking Ground - Integrating Biosimilar products into Hospital Care
This presentation will explore the comprehensive landscape of biosimilar biologics in oncology therapy and adopting them in a hospital setting. We'll delve into understanding the distinctions between reference and biosimilar biologics, Health Canada's approval process, and the pivotal role biosimilars play in fostering a sustainable healthcare system. Moreover, we'll discuss vital factors for evaluating biosimilars in hospital settings, such as cost-saving potential, supply chain considerations, and strategies for seamless implementation. Additionally, we'll highlight actionable strategies to promote biosimilar adoption within hospitals, emphasizing stakeholder engagement and pharmacist empowerment. Practical examples will offer insights into navigating challenges and achieving successful integration.
Learning Objectives:
- Describe the differences between reference biologics and biosimilar biologics
- Describe the process by which biosimilar biologics are approved and regulated by Health Canada
- Describe operational changes required for a Hospital Pharmacy to incorporate biosimilars into their formulary system and policies
- Define factors for considering adoption of biosimilars in Oncology
- Learn from practical examples, expected challenges and strategies to achieve a successful implementation
Presented by:
Flay Charbonneau
Manager, Odette Cancer Pharmacy, Sunnybrook Health Sciences Centre, Toronto, ON.
Jonathan Shloush
Process Coordinator- Systemic Therapy, Odette Cancer Pharmacy, Sunnybrook Health Sciences Centre, Toronto, ON.